Histone code reader SPIN1 is a promising target of cancer therapy

Biochimie ◽  
2021 ◽  
Vol 191 ◽  
pp. 78-86
Author(s):  
Di Li ◽  
Jihua Guo ◽  
Rong Jia
2014 ◽  
Vol 14 (6) ◽  
pp. 549-556 ◽  
Author(s):  
Xiantao Ye ◽  
Lixia Wang ◽  
Bingxue Shang ◽  
Zhiwei Wang ◽  
Wenyi Wei

2021 ◽  
Author(s):  
Tensho Ten ◽  
Satoru Nagatoishi ◽  
Masaru Hoshino ◽  
Yoshiki Nakayama ◽  
Motoharu Seiki ◽  
...  

Mint3 is known to enhance aerobic ATP production, known as the Warburg effect, by binding to FIH-1. Since this effect is considered to be beneficial for cancer cells, the interaction is a promising target for cancer therapy. However, previous research has suggested that the interacting region of Mint3 with FIH-1 is intrinsically disordered, which makes investigation of this interaction challenging. Therefore, we adopted a physicochemical approach that combined thermodynamic studies with structural analyses in solution, to clarify the binding mechanism. First, using a combination of CD, NMR, and hydrogen/deuterium exchange mass spectrometry (HDX-MS), we confirmed that the N-terminal half, which is the interacting part of Mint3, is mostly disordered. Next, using isothermal titration calorimetry (ITC), we revealed that the interaction of Mint3 and FIH-1 produces an enormous change in enthalpy and entropy. The profile is consistent with the model that the flexibility of disordered Mint3 is drastically reduced upon binding to FIH-1. Moreover, we performed a series of ITC experiments with several types of truncated Mint3s, an effective approach since the interacting part of Mint3 is disordered, and identified 78-88 as a novel core site for binding to FIH-1. The truncation study of Mint3 also revealed the thermodynamic contribution of each part to the interaction, where one contributes to the affinity (ΔG), while the other only affects enthalpy (ΔH), by forming non-covalent bonds. This insight can serve as a foothold for further investigation of IDRs and drug development for cancer therapy.


2020 ◽  
Vol 27 (1) ◽  
pp. 107327482097666
Author(s):  
Xianwang Wang ◽  
Yong Sun ◽  
Xiaochun Peng ◽  
Syed Manzar Abbas Shah Naqvi ◽  
Yue Yang ◽  
...  

Sphingosine kinase 1 (SPHK1) regulates cell proliferation and survival by converting sphingosine to the signaling mediator sphingosine 1-phosphate (S1P). SPHK1 is widely overexpressed in most cancers, promoting tumor progression and is associated with clinical prognosis. Numerous studies have explored SPHK1 as a promising target for cancer therapy. However, due to insufficient knowledge of SPHK1 oncogenic mechanisms, its inhibitors’ therapeutic potential in preventing and treating cancer still needs further investigation. In this review, we summarized the metabolic balance regulated by the SPHK1/S1P signaling pathway and highlighted the oncogenic mechanisms of SPHK1 via the upregulation of autophagy, proliferation, and survival, migration, angiogenesis and inflammation, and inhibition of apoptosis. Drug candidates targeting SPHK1 were also discussed at the end. This review provides new insights into the oncogenic effect of SPHK1 and sheds light on the future direction for targeting SPHK1 as cancer therapy.


2021 ◽  
Vol 22 (22) ◽  
pp. 12333
Author(s):  
Elvira Crescenzi ◽  
Antonio Leonardi ◽  
Francesco Pacifico

The signaling network between cancer and stromal cells plays a crucial role in tumor microenvironment. The fate of tumor progression mainly depends on the huge amount of information that these cell populations exchange from the onset of neoplastic transformation. Interfering with such signaling has been producing exciting results in cancer therapy: just think of anti-PD-1/anti-PD-L1/anti-CTLA-4 antibodies that, acting as immune checkpoint inhibitors, interrupt the inhibitory signaling exerted by cancer cells on immune cells or the CAR-T technology that fosters the reactivation of anti-tumoral immunity in a restricted group of leukemias and lymphomas. Nevertheless, many types of cancers, in particular solid tumors, are still refractory to these treatments, so the identification of novel molecular targets in tumor secretome would benefit from implementation of current anti-cancer therapeutical strategies. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a secreted protein abundantly expressed in the secretome of various human tumors. It represents a promising target for the multiple roles that are played inside cancer and stromal cells, and also overall in their cross-talk. The review focuses on the different roles of NGAL in tumor microenvironment and in cancer senescence-associated secretory phenotype (SASP), highlighting the most crucial functions that could be eventually targetable in cancer therapy.


Oncotarget ◽  
2016 ◽  
Vol 7 (20) ◽  
pp. 29480-29491 ◽  
Author(s):  
Juan Ma ◽  
Pan Ma ◽  
Chenghai Zhao ◽  
Xin Xue ◽  
Huamin Han ◽  
...  

2019 ◽  
Vol 90 (5) ◽  
Author(s):  
Jinming Zhao ◽  
Shanshan Zhong ◽  
Xing Niu ◽  
Jiwei Jiang ◽  
Ruochen Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document